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1. Introduction1
Vascular dementia is a severe cognitive dysfunction syn-
drome caused by cerebral vascular disease such as isch-
emic stroke, hemorrhagic stroke, memory, cognition and 
behavior. It is one of the important causes of senile demen-
tia. The main types of vascular dementia include acute vas-
cular dementia (including multiple infarction dementia, 
a critical site of infarction dementia, watershed infarction 
dementia and hemorrhagic dementia), and subacute or 
chronic vascular dementia (including subcortical athero-
sclerotic encephalopathy and the autosomal dominant ce-
rebral artery disease associated with subcortical infarction 
and white matter encephalopathy). The main clinical man-
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ifestations of patients were cognitive impairment, memory 
loss, or accompanied by language problem, behavioral 
changes, limb function and other retardation.
As China’s people gradually entered the aging stage, the 
incidence of cerebrovascular disease is increasing. Accord-
ing to statistics, the number of vascular dementia caused 
by cerebrovascular disease is increasing for about 26% [1]. 
The occurrence of vascular dementia in the elderly health 
is large. This health problem will impact the quality of 
life and caused serious influence. As a result, it will bring 
painful mental burden and huge economic burden to the 
patient’s family and society. Therefore, the combined ap-
plication of oxiracetam and hyperbaric oxygen on vascular 
dementia patient on treatment by obtaining the ideal cura-
tive effect were observed. The results were reported as fol-
lows.
2. Materials and methods
2.1. General information
From June 2013 to June 2014, there were 96 cases of vascu-
lar dementia patients have been treated. Two criteria have 
been considered which are inclusion and exclusion. Inclu-
sion criteria are the people who are at age of 40 years old, 
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months or more. Diagnostic criteria has been developed in 
order to meet the fourth edition of the American mental 
disorder diagnosis and Statistical Manual (DSM-IV) and 
nerve disease and stroke research institute [2]. Exclusion 
criteria: (1) The evaluation of other diseases which may af-
fect the results; (2) Patients who have complicated severe 
nerve defects, including aphasia and agnosia problems; 
(3) Patients who know the cause of dementia from other 
diseases; (4) Patients with severe heart, liver, kidney and 
hematopoietic function problems; (5) Patients who are suf-
fering from mental illness and severe diabetes; (6) Patients 
who has active epilepsy. The baseline examination were 
taken 2 weeks before by examining the brain cell activator, 
such as choline piracetam, brain protein hydrolysate, cell 
Diphosphate Choline and cholinesterase inhibitors and 
other drugs. Randomly, 96 patients were divided into three 
groups in which 32 cases in each group of patients who 
take the hyperbaric oxygen therapy, oxiracetam therapy 
and combined therapy, respectively. General data of pa-
tients in the three groups have no significant difference (p 
> 0.05), thus there is comparability.
2.2. Treatment method
Three groups of patients were given active treatment of ba-
sic diseases, including anti platelet to promote cerebral cir-
culation and cerebral protective agent. Hyperbaric oxygen 
therapy group (A group): 1 hour daily hyperbaric oxygen 
therapy. Oxiracetam group (B group): Intravenously ox-
iracetam injection (4.0 g with 250 mL of physiological sa-
line) one times per day. Hyperbaric oxygen combined with 
oxiracetam group (C group): use the method as mentioned 
above. Three groups of patients were treated for 3 consecu-
tive weeks. Patients with coronary heart disease and hyper-
tension have been treated with corresponding drugs.
2.3. Efficacy evaluation criteria
Before and after the treatment, the two groups of patients 
undergo Mini Mental State Examination scale (MMSE) as-
sessment with score range 0‒30 and for score less than 26 
points it is considered having the cognitive barriers. The 
lower the score, the more serious the degree of demen-
tia. For Activities of Daily Living (ADL) scale, for score 
less than 16 points is normal, for 17‒24 points indicate 
the problem of brain recognition ability, while for score is 
equal or greater than 25, it indicate that the need of brain 
repairment for loss of function [3].
Results were compared with before and after the treat-
ment; the simple mental state examination scale (MMSE) 
score increased by 3 points or more is consider excellent 
while for effective results the MMSE score is increased 1 to 
2 points. However, MMSE score is invalid when results are 
decreased by less than 1 point.
2.4. Statistical data processing
SPSS 18.0 software was used to analyze and count data for 
Chi-Square test while the measurement data were com-
pared with t-test. The single factor analysis of variance 
among groups was carried out, and the difference was sta-
tistically significant (p < 0.05).
3. Results
3.1. Clinical curative effect of three groups
After 3 weeks of treatment, the MMSE score of the two 
groups were significantly higher than that of the same 
group before treatment and the difference was statistically 
significant. The total effective rate of B group was 81.25%, 
and the total effective rate of C group was 93.75%, which 
was significantly higher than that of A group, and also the 
difference was statistically significant. See Table 1.
Table 1. Clinical efficacy of the three groups [cases (%)].
Group Cases Excellence Effective Invalid Total 
Efficiency
A Group 32 10 (31.25) 8 (25.00) 14 (43.75) 56.25
B Group 32 15 (46.88) 11 (34.38) 6 (18.75) 81.25*
C Group 32 16 (50.00) 14 (43.75) 2 (6.25) 93.75**
Note: Compared with A group, *p < 0.05, **p < 0.01.
3.2. MMSE scores before and after treatment in three 
groups
There were significant differences in MMSE scores between 
the three groups before and after treatment (p < 0.05). Al-
though the change of MMSE scores in C group was signifi-
cantly higher than that in B group and A group (p < 0.05), 
the different was statistical significance, see Table 2.
Table 2. MMSE scores of three groups before and after treat-






A Group 32 16.86 ± 3.12 18.13 ± 3.13*
B Group 32 16.91 ± 3.21 18.64 ± 2.92*
C Group 32 16.83 ± 3.13 20.82 ± 2.81**
Note: Compared with the prior treatment, *p < 0.05; B group and 
A group, **p < 0.05.
3.3. Side effects
There were no obvious side effects in the three groups.
4. Discussion
Vascular dementia (VD) is one of the mental disorders 
caused by cerebrovascular disease. The brain function 
of patients with dementia is decreased for at least a few 
months, especially with the recession of the intelligence 
related function, for example, the patient’s mood, behav-
ior, memory and cognitive force and other symptoms pre-
sented as signs of a recession. The differential diagnostic 
criteria of vascular dementia are many, including: (1) The 
cognitive and social function was significantly decreased. 
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(2) The basis of cerebrovascular disease was confirmed by 
medical history, clinical manifestations, and the auxiliary 
examination. (3) Dementia occurred within 3‒6 months 
after cerebral vascular disease [4].
Differential diagnosis of typical symptoms of Vascular 
dementia is categorized into four types: (1) Alzheimer’s 
disease (AD) and its insidious onset: slow progress, loss 
outstanding memorycognitive dysfunction and personal-
ity changes. Neuroimaging findings show significant cere-
bral cortex atrophy with ischemic volume table is less than 
or equal to 4 points (improved ischemia volume table is 
less than or equal to 2 points) to support the diagnosis of 
AD; (2) Pick’s disease, ascended to the throne of dementia 
show early obvious personality change and social behav-
ior disorders, language impairment, memory and cogni-
tive function disorder relatively late. CT or MRI is mainly 
significant for frontal and / or temporal lobe atrophy; (3) 
Dementia with Lewy Bodies (DLB) where the volatility of 
cognitive impairment, repeated vivid visual hallucinations 
and extrapyramidal symptoms. However, imaging observa-
tion show no infarction and no signs of localization neuro-
logical examination; (4) Parkinson’s disease with dementia 
and its early appear extrapyramidal involvement symptoms 
such as tremor, myotonia, in attention, calculation, visual 
spatial memory, etc. mainly damaged [5].
Oxiracetam in chemical structure belongs to a kind of 
amino acid derivatives. The cerebral cortex and hippocam-
pus that play protection and activation can activate adeny-
late cyclase which increases the synthesis of protein and 
nucleic acid in the brain and acting on aspartate (NMDA) 
receptor. Thus, it will affect long-term potentiation (LTP) 
generation by increased acetylcholine in cortex and hip-
pocampus and the transport of choline uptake. Besides, it 
is also increase affinity, promote brain metabolism and im-
prove cerebral oxygen utilization of glucose in which con-
tribute to the repair of nerve cell function. Moreover, ox-
iceratam also can improve memory and learning ability of 
patients with mental retardation by activation, protection 
and repair of nerve cells so that the brain has a protective 
effect on hypoxia [6]. Oxiracetam can improve the patient’s 
mental state and reduce the degree of dementia with no 
side effect.
Hyperbaric oxygen can also be effective in the treatment 
of vascular dementia. Hyperbaric oxygen therapy is the 
process of treating the disease with high concentrations 
of oxygen above than that in the atmospheric pressure. 
The therapeutic mechanism are: (1) High pressure oxy-
gen can effectively improve blood pressure by enhanced 
blood oxygen dispersion ability and correct brain damage 
to the hypoxic state; (2) Cerebral blood flow by improv-
ing the blood flow of vertebral artery which can activate 
the network system and oxygen partial pressure. After all, 
this method can increase the oxygen partial pressure and 
oxygen content of the body which relieve the oxygen sup-
ply of brain tissue and increase the blood oxygen supply to 
improve microcirculation abnormality. Thus it exerts the 
effect of preventing and treating vascular dementia [7].
The results of this study showed that the change of 
MMSE scores of the combined treatment group was the 
most significant, and there was statistical significance. In 
summary, combined oxiracetam with hyperbaric oxygen 
therapy can be effective in improving vascular dementia 
patients with mental retardation and increase the ability of 
activities in daily life. The efficacy and safety of the method 
is proved in order to be as clinical promotion.
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